SRZN - Surrozen, Inc./DE
9.25
-0.610 -6.595%
Share volume: 9,181
Last Updated: 05-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$9.86
-0.61
-0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-08-2024 | 08-12-2024 | 11-06-2024 | |
| Total revenue | 0.000 | 0.000 | 10.000 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 10.000 M | |
| nan% | inf% | |||
| Operating expenses | 9.130 M | 9.049 M | 8.768 M | |
| Selling general and admin | 3.883 M | 3.714 M | 3.568 M | |
| Research and development | 5.247 M | 5.335 M | 5.200 M | |
| Total expenses | 9.130 M | 9.049 M | 8.768 M | |
| -0.89% | -3.11% | |||
| Operating income | -9.130 M | -9.049 M | 1.232 M | |
| Ebit | -9.215 M | -25.751 M | -1.865 M | |
| Pretax income | -8.830 M | -25.261 M | -1.434 M | |
| 186.08% | -94.32% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -8.830 M | -25.261 M | -1.434 M | |
| -186.08% | 94.32% |
